A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial

Published:2020-05 Issue:5 Volume:39 Page:1379-1384
ISSN:0261-5614
Container-title:Clinical Nutrition
language:en
Short-container-title:Clinical Nutrition

Author:

Mercurio Valentina^ORCID,Pucci Giacomo,Bosso Giorgio,Fazio Valeria,Battista Francesca,Iannuzzi Angela,Brambilla Nadia,Vitalini Cristina,D'Amato Massimo,Giacovelli Giampaolo,Vaudo Gaetano,Schillaci Giuseppe,Galletti Ferruccio,Bonaduce Domenico

Funder

Rottapharm SpA

Publisher

Elsevier BV

Subject

Critical Care and Intensive Care Medicine,Nutrition and Dietetics

Reference23 articles.

1. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study;Laaksonen;Am J Epidemiol,2002

2. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension;Schillaci;Hypertension,2000

3. Metabolic syndrome and target organ damage in untreated essential hypertensives;Cuspidi;J Hypertens,2004

4. Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women;Schillaci;Hypertension,2006

5. Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study;de Simone;Nutr Metab Cardiovasc Dis,2009

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Independent risk factors of left ventricular hypertrophy in non-diabetic individuals in Sierra Leone - a cross-sectional study;Lipids in Health and Disease;2024-08-21

2. A systematic, updated review of Xuezhikang, a domestically developed lipid-lowering drug, in the application of cardiovascular diseases;Acta Pharmaceutica Sinica B;2024-05

3. Insulin Resistance/Hyperinsulinemia, Neglected Risk Factor for the Development and Worsening of Heart Failure with Preserved Ejection Fraction;Biomedicines;2024-04-04

4. Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated;Frontiers in Cardiovascular Medicine;2024-03-13

5. Hypertensive Heart Disease: Mechanisms, Diagnosis and Treatment;Reviews in Cardiovascular Medicine;2024-03-06